来自MSN1 天
Certain Glucose-Lowering Meds Associated With Lower Risk for COPD Exacerbations
For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 ...
Chime Biologics Supports Mabgeek to Enter the U.S. Phase III Trials for MG-K10
Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced its continued ...
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag
The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.
Too Old to Operate4 天
Dupilumab and Airway Imaging in Moderate-to-Severe Type 2 Asthma
The following is a summary of “Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging ...
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of ...
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...
Le Lézard5 天
Aveva Drug Delivery Systems Launches Generic Fentanyl TDS, it's Third Successful Complex ...
Aveva Drug Delivery systems (A DifGen company), a leader in transdermal drug delivery systems based out of Miramar - Florida is proud to announce the launch of all strengths of its generic Fentanyl ...
Healio5 天
Rezpegaldesleukin gets FDA fast track designation for atopic dermatitis
The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate ...
Daily6 天
Dupilumab significantly Reduces COPD Exacerbations in Phase 3 Trials
Researchers have found in a phase 3 trials that Dupilumab significantly reduced moderate or severe COPD exacerbations ...